M&A Deal Summary

United Therapeutics Acquires SteadyMed

On August 30, 2018, United Therapeutics acquired medical products company SteadyMed for 216M USD

Acquisition Highlights
  • This is United Therapeutics’ 1st transaction in the Medical Products sector.
  • This is United Therapeutics’ largest (disclosed) transaction.
  • This is United Therapeutics’ 2nd transaction in the United States.
  • This is United Therapeutics’ 1st transaction in California.

M&A Deal Summary
Date 2018-08-30
Target SteadyMed
Sector Medical Products
Buyer(s) United Therapeutics
Deal Type Add-on Acquisition
Deal Value 216M USD
Advisor(s) Wedbush Securities, Inc. (Financial)
Cooley
Arnon, Tadmor-Levy (Legal)

Target

SteadyMed

San Ramon, California, United States
SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent, a development-stage drug-device combination product that combines SteadyMed's PatchPump technology with treprostinil, a vasodilatory prostacyclin analogue to treat PAH. SteadyMed has signed an exclusive license and supply agreement with Cardiome Pharma Corp.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

United Therapeutics

Silver Spring, Maryland, United States
Category Company
Founded 1996
Sector Medical Products
Employees950
Revenue 2.3B USD (2023)
DESCRIPTION

United Therapeutics is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. United Therapeutics was founded in 1996 and is based in Silver Spring, Maryland.

DEAL STATS #
Overall 2 of 4
Sector (Medical Products) 1 of 1
Type (Add-on Acquisition) 2 of 3
State (California) 1 of 1
Country (United States) 2 of 4
Year (2018) 1 of 1
Size (of disclosed) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-08-19 Rare Pediatric Disease Priority Review Voucher

United States

Rare Pediatric Disease Priority Review Voucher (PPRV) is a provider of biotechnology services.

Sell $350M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-12-28 Rare Pediatric Disease Priority Review Voucher

United States

Rare Pediatric Disease Priority Review Voucher (PPRV) is a provider of biotechnology services.

Buy $105M
Mergr

Product

Company

Legal